1 – 10 of 22
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
COMBAT-MS : A Population-Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
2024) In Annals of Neurology(
- Contribution to journal › Article
-
Mark
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden : An observational cohort study
(
- Contribution to journal › Article
- 2023
-
Mark
Cerebrospinal fluid levels of neuroinflammatory biomarkers are increased in athletes with persistent post-concussive symptoms following sports-related concussion
(
- Contribution to journal › Article
-
Mark
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
2023) In Journal of Neurology, Neurosurgery and Psychiatry(
- Contribution to journal › Article
-
Mark
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort
(
- Contribution to journal › Article
- 2022
-
Mark
COVID-19 clinical outcomes and DMT of MS patients and population-based controls
(
- Contribution to journal › Article
-
Mark
Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia
(
- Contribution to journal › Article
- 2020
-
Mark
A novel, robust method for quantification of multiple kynurenine pathway metabolites in the cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects
(
- Contribution to journal › Article
-
Mark
Quantification of Plasma Kynurenine Metabolites Following One Bout of Sprint Interval Exercise
(
- Contribution to journal › Article